中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

CC亚族趋化因子及其受体在慢性肝病中的作用及机制

张子欣 李晖 王佳慧 陶雨静 曾小晏

引用本文:
Citation:

CC亚族趋化因子及其受体在慢性肝病中的作用及机制

DOI: 10.12449/JCH240528
基金项目: 

国家自然科学基金面上项目 (82274323)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:张子欣负责撰写论文;王佳慧,陶雨静,曾小晏参与收集文献,修改论文;李晖负责拟定写作思路,指导文章撰写并最后定稿。
详细信息
    通信作者:

    李晖, 1400124746@qq.com (ORCID: 0000-0002-5919-1396)

Role and mechanism of CC chemokines and their receptors in chronic liver diseases

Research funding: 

General Program of the National Natural Science Foundation of China (82274323)

More Information
    Corresponding author: LI Hui, 1400124746@qq.com (ORCID: 0000-0002-5919-1396)
  • 摘要: 近年来,慢性肝病的发病率持续上升,如慢性乙型肝炎、非酒精性脂肪性肝病、肝纤维化、肝硬化、肝细胞癌等,且发病年龄逐渐呈现低龄化趋势。目前许多CC亚族趋化因子在慢性肝病中的作用得到了证实,本文对近年来影响慢性肝病的CC亚家族趋化因子及其受体的研究进展进行总结,探讨其在慢性肝病中的应用潜力,以期为慢性肝病的防治研究提供新思路。

     

  • 图  1  CC亚族趋化因子及其受体在慢性肝病中的作用机制

    Figure  1.  Mechanism of CC subfamily chemokines and receptors in chronic liver disease

    表  1  CC亚族趋化因子及其受体在慢性肝病中的作用

    Table  1.   Role of CC subfamily chemokines and receptors in chronic liver disease

    趋化因子 趋化因子受体 在慢性肝病中的作用
    CCL1 CCR8 CCR8促进炎性单核细胞向损伤肝脏的迁移,并使其分化为具有促炎表型的巨噬细胞,发挥促纤维化作用
    CCL2 CCR2 CCL2与其受体CCR2结合招募单核-巨噬细胞到损伤的肝脏,抑制CCL2的表达,可减少肝纤维化- HCC动物模型中的Ⅰ型胶原、Ⅳ型胶原和病理性血管生成,从而改善肝脏结构紊乱,高浓度CCL2及其受体可对单核/巨噬细胞积聚、炎症过程启动以及纤维蛋白生成产生影响,并促进癌症的发生
    CCL3/CCL5 CCR1/CCR5 CCL3表达促进了HSC的增殖和迁移、促进巨噬细胞浸润到肝脏,分化为M1表型,CCL3缺乏可减轻小鼠肝纤维化。CCL3可以向HCC募集白细胞,促进HCC的发生。CCL3是NAFLD进展的致病因素。CCL5可通过ROS的产生、Akt/ERK的信号传导,诱导HSC迁移;并在纤维化和伤口愈合过程中,招募CCR5阳性的肝祖细胞。CCR5和CCR1在慢性肝损伤的情况下可以促进肝纤维化。CVC是CCR2/CCR5双重拮抗剂,通过抑制炎症性FSCN1+巨噬细胞和HERC6+中性粒细胞的肝脏积聚来改善细胞外基质沉积和肝纤维化。CCL5为HCC诊断的潜在生物标志物,CCL5的灵敏度和特异度较CCL4更高
    CCL4 CCL4为HCC诊断的潜在生物标志物
    CCL11 CCL11通过刺激Jagged 1的转录以调节HSC的活化,发挥促纤维化的作用
    CCL14 CCL14为肿瘤抑制因子,可用于判断HCC患者的预后
    CCL15 CCL15的高表达与HCC患者的不良预后相关
    CCL16 CCL16通过使HSC失活抑制肝硬化的进展,并可作为肝硬化发生、进展的标志物
    CCL17 CCR4 CCL17可募集Th17细胞、细胞毒性T淋巴细胞到慢性乙型肝炎患者的肝组织中,阻断CCR4可重建T淋巴细胞抗病毒的免疫应答,并限制Treg的免疫抑制功能,有望成为慢性乙型肝炎的潜在治疗靶点
    CCL19 过表达CCL19,可通过增加肝内CD8+T淋巴细胞,快速清除肝内HBV
    CCL20 CCR6 CCL20可招募巨噬细胞和HSC,并通过激活HSC,发挥促炎及促肝纤维化的作用
    CCL25 CCR9 在NASH小鼠巨噬细胞招募和肝纤维化形成中发挥重要作用。CCR9拮抗剂可阻碍肝纤维化、脂肪性肝炎和HCC进展
    下载: 导出CSV
  • [1] GRIFFITH JW, SOKOL CL, LUSTER AD. Chemokines and chemokine receptors: Positioning cells for host defense and immunity[J]. Annu Rev Immunol, 2014, 32: 659- 702. DOI: 10.1146/annurev-immunol-032713-120145.
    [2] EDDERKAOUI B. Potential role of chemokines in fracture repair[J]. Front Endocrinol(Lausanne), 2017, 8: 39. DOI: 10.3389/fendo.2017.00039.
    [3] FAHEY S, DEMPSEY E, LONG A. The role of chemokines in acute and chronic hepatitis C infection[J]. Cell Mol Immunol, 2014, 11( 1): 25- 40. DOI: 10.1038/cmi.2013.37.
    [4] WASMUTH HE, TACKE F, TRAUTWEIN C. Chemokines in liver inflammation and fibrosis[J]. Semin Liver Dis, 2010, 30( 3): 215- 225. DOI: 10.1055/s-0030-1255351.
    [5] GUSTAVSSON M. New insights into the structure and function of chemokine receptor: Chemokine complexes from an experimental perspective[J]. J Leukoc Biol, 2020, 107( 6): 1115- 1122. DOI: 10.1002/JLB.2MR1219-288R.
    [6] CHARO IF, RANSOHOFF RM. The many roles of chemokines and chemokine receptors in inflammation[J]. N Engl J Med, 2006, 354( 6): 610- 621. DOI: 10.1056/NEJMra052723.
    [7] BAGGIOLINI M, LOETSCHER P. Chemokines in inflammation and immunity[J]. Immunol Today, 2000, 21( 9): 418- 420. DOI: 10.1016/s0167-5699(00)01672-8.
    [8] SALLUSTO F, MACKAY CR, LANZAVECCHIA A. The role of chemokine receptors in primary, effector, and memory immune responses[J]. Annu Rev Immunol, 2000, 18: 593- 620. DOI: 10.1146/annurev.immunol.18.1.593.
    [9] WHITE GE, IQBAL AJ, GREAVES DR. CC chemokine receptors and chronic inflammation: Therapeutic opportunities and pharmacological challenges[J]. Pharmacol Rev, 2013, 65( 1): 47- 89. DOI: 10.1124/pr.111.005074.
    [10] SEEGER C, MASON WS. Molecular biology of hepatitis B virus infection[J]. Virology, 2015, 479-480: 672- 686. DOI: 10.1016/j.virol.2015.02.031.
    [11] HU LS, ZHU Y, ZHANG JQ, et al. Potential circulating biomarkers of circulating chemokines CCL5, MIP-1β and HA as for early detection of cirrhosis related to chronic HBV(hepatitis B virus) infection[J]. BMC Infect Dis, 2019, 19( 1): 523. DOI: 10.1186/s12879-019-4130-0.
    [12] LI Y, WANG CM, ZHAO T, et al. Hepatitis B virus X protein modulates chemokine CCL15 upregulation in hepatocellular carcinoma[J]. Anticancer Agents Med Chem, 2021, 21( 16): 2198- 2203. DOI: 10.2174/1871520621666210302083407.
    [13] ZHANG K, LIU YQ, YANG XA, et al. HBV promotes the recruitment of IL-17 secreting T cells via chemokines CCL22 and CCL17[J]. Liver Int, 2020, 40( 6): 1327- 1338. DOI: 10.1111/liv.14438.
    [14] ZHUO JY, LU D, LIN ZY, et al. CC motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells[J]. Hepatobiliary Pancreat Dis Int, 2020, 19( 5): 440- 448. DOI: 10.1016/j.hbpd.2019.12.006.
    [15] YAN Y, ZHAO W, LIU W, et al. CCL19 enhances CD8+ T-cell responses and accelerates HBV clearance[J]. J Gastroenterol, 2021, 56( 8): 769- 785. DOI: 10.1007/s00535-021-01799-8.
    [16] KHANAM A, GHOSH A, CHUA JV, et al. Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways[J]. J Transl Med, 2023, 21( 1): 271. DOI: 10.1186/s12967-023-04104-8.
    [17] LIU HJ, GUAN QZ, ZHAO P, et al. TGF-β-induced CCR8 promoted macrophage transdifferentiation into myofibroblast-like cells[J]. Exp Lung Res, 2022: 1- 14. DOI: 10.1080/01902148.2022.2055227.
    [18] LI L, WEI W, LI ZZ, et al. The spleen promotes the secretion of CCL2 and supports an M1 dominant phenotype in hepatic macrophages during liver fibrosis[J]. Cell Physiol Biochem, 2018, 51( 2): 557- 574. DOI: 10.1159/000495276.
    [19] BARTNECK M, SCHRAMMEN PL, MÖCKEL D, et al. The CCR2+ macrophage subset promotes pathogenic angiogenesis for tumor vascularization in fibrotic livers[J]. Cell Mol Gastroenterol Hepatol, 2019, 7( 2): 371- 390. DOI: 10.1016/j.jcmgh.2018.10.007.
    [20] FLAMINI S, SERGEEV P, VIANA de BARROS Z, et al. Glucocorticoid-induced leucine zipper regulates liver fibrosis by suppressing CCL2-mediated leukocyte recruitment[J]. Cell Death Dis, 2021, 12( 5): 421. DOI: 10.1038/s41419-021-03704-w.
    [21] XI S, ZHENG X, LI X, et al. Activated hepatic stellate cells induce infiltration and formation of CD163+ macrophages via CCL2/CCR2 pathway[J]. Front Med(Lausanne). 2021, 8: 627927. DOI: 10.3389/fmed.2021.627927.
    [22] DU PLESSIS J, KORF H, van PELT J, et al. Pro-inflammatory cytokines but not endotoxin-related parameters associate with disease severity in patients with NAFLD[J]. PLoS One, 2016, 11( 12): e0166048. DOI: 10.1371/journal.pone.0166048.
    [23] XU L, CHEN YP, NAGASHIMADA M, et al. CC chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice[J]. Metabolism, 2021, 125: 154914. DOI: 10.1016/j.metabol.2021.154914.
    [24] GUO YK, ZHAO C, DAI WT, et al. C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape[J]. Int J Biol Sci, 2023, 19( 8): 2572- 2587. DOI: 10.7150/ijbs.83530.
    [25] IGAKI K, KOMOIKE Y, NAKAMURA Y, et al. MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model[J]. Int Immunopharmacol, 2018, 60: 160- 169. DOI: 10.1016/j.intimp.2018.04.049.
    [26] MORIKAWA R, NAKAMOTO N, AMIYA T, et al. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis[J]. J Hepatol, 2021, 74( 3): 511- 521. DOI: 10.1016/j.jhep.2020.09.033.
    [27] HANSON A, PIRAS IS, WILHELMSEN D, et al. Chemokine ligand 20(CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p[J]. Cytokine, 2019, 123: 154789. DOI: 10.1016/j.cyto.2019.154789.
    [28] HEO YJ, CHOI SE, LEE NM, et al. CCL20 induced by visfatin in macrophages via the NF-κB and MKK3/6-p38 signaling pathways contributes to hepatic stellate cell activation[J]. Mol Biol Rep, 2020, 47( 6): 4285- 4293. DOI: 10.1007/s11033-020-05510-7.
    [29] KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 151- 166. DOI: 10.1038/s41575-020-00372-7.
    [30] KONG M, DONG WH, KANG AQ, et al. Regulatory role and translational potential of CCL11 in liver fibrosis[J]. Hepatology, 2023, 78( 1): 120- 135. DOI: 10.1097/HEP.0000000000000287.
    [31] PROOST P, WUYTS A, van DAMME J. The role of chemokines in inflammation[J]. Int J Clin Lab Res, 1996, 26( 4): 211- 223. DOI: 10.1007/BF02602952.
    [32] TACKE F. Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo[J]. Fibrogenesis Tissue Repair, 2012, 5( Suppl 1): S27. DOI: 10.1186/1755-1536-5-S1-S27.
    [33] DEBES JD, ROMAGNOLI PA, PRIETO J, et al. Serum biomarkers for the prediction of hepatocellular carcinoma[J]. Cancers(Basel), 2021, 13( 7): 1681. DOI: 10.3390/cancers13071681.
    [34] ZHU MX, XU WY, WEI CY, et al. CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis[J]. Cell Death Dis, 2019, 10( 11): 796. DOI: 10.1038/s41419-019-1966-6.
    [35] EHLING J, TACKE F. Role of chemokine pathways in hepatobiliary cancer[J]. Cancer Lett, 2016, 379( 2): 173- 183. DOI: 10.1016/j.canlet.2015.06.017.
    [36] YANG XQ, LU PR, FUJII C, et al. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression[J]. Int J Cancer, 2006, 118( 8): 1869- 1876. DOI: 10.1002/ijc.21596.
    [37] PAN XF, CHIWANDA KAMINGA A, LIU AZ, et al. Chemokines in non-alcoholic fatty liver disease: A systematic review and network meta-analysis[J]. Front Immunol, 2020, 11: 1802. DOI: 10.3389/fimmu.2020.01802.
    [38] TAN YY, YUE SR, LU AP, et al. The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis[J]. Phytomedicine, 2022, 103: 154208. DOI: 10.1016/j.phymed.2022.154208.
    [39] RATZIU V, SANYAL A, HARRISON SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b CENTAUR study[J]. Hepatology, 2020, 72( 3): 892- 905. DOI: 10.1002/hep.31108.
    [40] WIERING L, TACKE F. Treating inflammation to combat non-alcoholic fatty liver disease[J]. J Endocrinol, 2022, 256( 1): e220194. DOI: 10.1530/JOE-22-0194.
    [41] PUENGEL T, LEFERE S, HUNDERTMARK J, et al. Combined therapy with a CCR2/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis[J]. Int J Mol Sci, 2022, 23( 12): 6696. DOI: 10.3390/ijms23126696.
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  430
  • HTML全文浏览量:  156
  • PDF下载量:  38
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-10-19
  • 录用日期:  2023-12-12
  • 出版日期:  2024-05-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回